19 June 2013
Keywords: favorable, tox, profile, bionovo, bzl101, drugmaker, focused
Article | 19 December 2005
Bionovo, a US drugmaker focused on cancer, says that encouraging Phase I data on its oral drug candidate, BZL101, were ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 December 2005
18 June 2013
© 2013 thepharmaletter.com